August 2012
-
Sunovion Pharmaceuticals and the American College of Chest Physicians (CHEST) have launched an initiative called “Delivery Makes a Difference,” which they say “seeks to understand patient and health care provider practices and to provide tools… Read more . . .
-
PPD has added 4,300 sq ft to its GMP biopharmaceuticals and inhalation facility in Athlone, Ireland, the company has announced. The facility, which opened in 2010 and offers a wide range of formulation, development, and… Read more . . .
-
Theravance Biopharma and Mylan have announced that two 12-week Phase 3 efficacy studies of nebulized revefenacin (TD-4208) for the treatment of COPD have met their primary efficacy endpoint of statistically significant increase in FEV1 for… Read more . . .
-
Propeller Health has closed on a $21.5 million Series C funding round to support expansion of its digital inhaler monitoring platform, the company said. Investors included 3M Ventures, S.R. One, Limited and Hikma Ventures, Safeguard… Read more . . .
-
Multistage cascade impaction is a core analytical technique for working with inhaled products, so understanding how cascade impactors work is crucial – but difficult. A new animation from impactor specialists Copley Scientific can help beginners… Read more . . .
-
Drawing on resources from the Lovelace Respiratory Research Institute (LRRI) and associated companies, a not-for-profit preclinical contract research organization called Lovelace Biomedical is now offering services for pre-clinical development. The new company’s services include toxicology,… Read more . . .
-
Mast Therapeutics has announced that its subsidiary Aires Pharmaceuticals has signed an agreement with Philips Respironics devices for the supply of I-neb AAD handheld nebulizers for delivery of the company’s AIR001 sodium nitrite solution. AIR001… Read more . . .
-
The FDA’s October 2016 release of new bioequivalence recommendations for specific products includes draft BE guidances for umeclidinium bromide inhalation powder (Incruse Ellipta), triamcinolone acetonide nasal spray (Nasacort), and olopatadine hydrochloride nasal spray (Patanase). For… Read more . . .
-
Drug delivery device design company Coalesce Product Development has announced the opening of a new 375 sq m drug delivery development center in Cambridge, UK as well as several management changes, including the appointment of… Read more . . .
-
The FDA has accepted Sunovion’s NDA for SUN-101 glycopyrrolate delivered by the PARI eFlow nebulizer for the treatment of COPD, the company said. The agency has set a PDUFA date of May 29, 2017 for… Read more . . .
Featured event:
5th Annual Inhaled & Nasal Biologics | DNA Forum
5th Annual Inhaled & Nasal Biologics | DNA Forum
24th-25th September 2026, Cambridge, UK
Join us for a ground-breaking and insightful forum: Two days of cutting-edge talks and networking opportunities in this complex area of drug and vaccine development.
With renowned industry leaders who will share their insights and real-world case studies, our speakers will explore innovative formulation and delivery technologies and the rationale behind overcoming development challenges. Don’t miss out on this opportunity to learn more about key topics shaping the future of inhaled therapeutics.
Get online to see speakers announced so far. Registration is live – save your seat now!
Upcoming Events
Sponsored by Intertek,, hosts of
The Inhaled & Nasal Biologics | DNA Forum
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
October 19-October 20: MVIC Autumn Training 2026, Lund, Sweden
October 21-October 22: MVIC Symposium, Lund, Sweden
November 10-November 11: Rescon Europe 2026, Porto, Portugal
December 9-December 11: DDL 2026, Edinburgh, Scotland